文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

脓毒症1年生存者的恶性肿瘤风险:一项基于登记系统的全国性随访研究

Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study.
PubMed 文献 · Crit Care · 2023-09-29
一句话结论瑞典全国登记数据显示,脓毒症1年生存者新发癌症风险高于一般人群,女性SIR 1.74、男性1.31,作者认为或需对脓毒症生存者进行恶性肿瘤监测。

该研究基于瑞典重症监护登记系统(SICR)2005—2017年成人ICU脓毒症入院数据,纳入有明确ICD-10脓毒症编码的1年生存者18550例,随访至2018年底,中位随访3.36年(IQR 1.72-5.86),累计75427人年。期间6366例(34.3%)死亡,1625例(8.8%)在中位2.51年(IQR 1.09-4.48)后诊断新发癌症。与一般人群(NORDCAN)比较,男性任何新发癌症的标准化发病比SIR为1.31(95%CI 1.23-1.40),女性为1.74(95%CI 1.61-1.88),差异在多项敏感性分析中持续存在,消化道、生殖器官和皮肤肿瘤的SIR最高。作者认为,脓毒症生存者或需接受恶性肿瘤监测。

要点

  • 脓毒症1年生存者新发癌症风险高于一般人群:男性SIR 1.31(95%CI 1.23-1.40),女性SIR 1.74(95%CI 1.61-1.88)。
  • 18550例1年生存者中,1625例(8.8%)在中位2.51年(IQR 1.09-4.48)后诊断新发癌症。
  • SIR最高的肿瘤为消化道、生殖器官和皮肤肿瘤。
  • 研究结论提示,脓毒症生存者或需接受恶性肿瘤监测,但随访时间不同结果有差异,提示除脓毒症外还有其他因素参与。

适用人群与场景

  • 2005—2017年瑞典重症监护登记系统(SICR)中,因脓毒症(有明确ICD-10编码)首次入住ICU的成人患者,且存活至1年者,构成最终队列。

研究设计与关键结果

  • 研究类型:基于登记系统的全国性随访研究;最终队列18550例1年生存者,中位随访3.36年(IQR 1.72-5.86),累计75427人年。
  • 随访期间6366例(34.3%)死亡;1625例(8.8%)诊断新发癌症,诊断新发癌症者的中位随访2.51年(IQR 1.09-4.48)。
  • 与一般人群(NORDCAN)比较,任何新发癌症的标准化发病比:男性SIR 1.31(95%CI 1.23-1.40),女性SIR 1.74(95%CI 1.61-1.88)。
  • 上述发病差异在多项敏感性分析中持续存在;SIR最高的癌症为消化道、生殖器官和皮肤肿瘤。

证据类型、等级与局限

  • 证据类型:基于登记系统的全国性随访研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,脓毒症生存者或需接受恶性肿瘤监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in 1-year sepsis survivors and test the hypothesis that it is higher than that of the general population.

METHODS: We obtained data on ICU admissions of adult patients from Swedish Intensive care registry (SICR) from 2005 to 2017. We included patients with an explicit ICD-10 code for sepsis for the primary ICU admission. We obtained data on cancer diagnoses (2001-2018), death (2005-2018) and emigration (2005-2018) from Cancer and Cause of death and National Patient Registry databases of the National Board of Health and Welfare; age and sex-specific cancer incidence rates in Sweden from NORDCAN registry from 2006 to 2018. One-year survivors formed the final cohort, that was followed for new cancer diagnoses until death, emigration, or end of 2018, whichever came first. The main outcome measure was standardized incidence rate ratio (SIR) to compare the incidence of cancer in 1-year sepsis survivors to that in the general population (NORDCAN). We also performed several sensitivity analyses.

RESULTS: In a cohort of 18,550 1-year survivors, 75,427 person years accumulated during a median follow-up (FU) of 3.36 years (IQR 1.72-5.86), 6366 (34.3%) patients died, and 1625 (8.8%) patients were diagnosed with a new cancer after a median FU of 2.51 (IQR 1.09-4.48) years. The incidence ratio of any new cancer over the whole FU was 1.31 (95% CI 1.23-1.40) for men and 1.74 (95% CI 1.61-1.88) for women. The difference in incidence rates persisted in several sensitivity analyses. The SIRs were highest in cancers of gastrointestinal tract, genital organs, and skin.

CONCLUSION AND RELEVANCE: Compared to general population, incidence of cancer is increased in 1-year sepsis survivors. Variation in the findings depending on follow-up time suggests that factors other than sepsis alone are involved. Surveillance for malignant disease may be warranted in sepsis survivors.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Hästbacka J, But A, Strandberg G, et al. Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study. Crit Care. 2023. PMID: 37773171. doi:10.1186/s13054-023-04654-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。